-
Mashup Score: 1
f 2700 community-dwelling Japanese residents aged ≥40 years were assessed for chronic pain and its components of duration, frequency, and intensity. The activities of daily living (ADL) disability and depressive symptoms of participants were also evaluated using the modified Lankin Scale and Patient Health Questionnaire-9. The odds ratios and the population attributable fractions (PAFs) for ADL disability and depressive symptoms were estimated using a logistic regression model. Results: The prevalence of chronic pain varied greatly by definition, ranging from 13% for pain defined as pain duration ≥3 months, pain frequency ≥ twice a week, and pain intensity of ≥50 mm by a visual analogue scale (VAS) to 48% for a simple definition of pain duration ≥3 months. The PAFs for ADL disability and depressive symptoms were relatively high at 33% in participants with pain duration of ≥6 months and 30% in those with pain frequency of ≥twice a week, while the VAS ≥50 mm group had a low PAF of 12%. C
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
jectives: We examined the analgesic efficacy of anodal tDCS over the left M1 of patients with severe PDM and studied the functional connectivity (FC) changes between the periaqueductal gray matter (PAG) and the medial motor area (MMA) to elucidate the possible central mechanisms. Methods: Twenty-eight patients with severe PDM participated in this randomized and sham-controlled study. The participants received daily M1-tDCS for 5 to 7 days, beginning 2 to 3 days before menstruation and continuing until their pain severity decreased to a mild level. We evaluated the menstrual pain and PAG-seeded FC with MMA using resting-state functional magnetic resonance imaging right after and 1 month later after M1-tDCS modulation. Results: The neuromodulation by active M1-tDCS led to a significant decrease in the FC between the PAG and MMA. This reduction in FC correlated with a decrease in menstrual pain experienced in the subsequent menstrual cycle. Notably, only the FC modulated by active M1-tDCS
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4April 2025 - Volume 10 - Issue 2 : PAIN Reports - 6 day(s) ago
The open home of global research and emerging pain science, PAIN Reports is an official publication of IASP. View free articles at and learn more today!
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
es patients experience with these medicines is important for the provision of care. Objective: To understand the difficulties experienced by patients prescribed opioids for noncancer pain in primary care. Methods: A cross-sectional postal survey of adults prescribed an opioid medicine for noncancer pain over a period of ≥3 months from 10 general practices (n = 3077) in the East Midlands was conducted using self-completed questionnaires. Sociodemographic, pain, and opioid use information was gathered to characterise the study population. An adapted version of the 15-item Prescribed Opioids Difficulties Scale was used to assess the problems and concerns attributed to using prescribed opioids, from the time opioids were first prescribed. Results: Questionnaires were received from 619 respondents (response rate = 20.1%), of whom 59.8% were female, and the median age was 64 years. Four in 5 (79.8%) had experienced at least one opioid problem or concern from the Prescribed Opioids Difficulti
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2
and high (HPS). However, the reliability of these haplotypes in predicting clinical outcomes is not well investigated. We present a 40-year-old female patient with fibromyalgia. Despite extensive pharmacotherapy with 120 mg/d duloxetine, 150 mg/d pregabalin, 80 mg/d oxycodone, 2 g/d paracetamol, and 1.6 g/d ibuprofen, she suffered from severe pain. Objectives: We aim to investigate the patient’s susceptibility to analgesic therapy failure (TF) and pain sensitivity with pharmacogenotyping. Methods: PGx panel testing, including CYP2D6 and COMT rs4680, was conducted by a commercial provider. Additional genotyping of COMT rs6269, rs4633 and rs4818 was performed applying PCR, restriction fragment length polymorphism assay and sanger sequencing. Results: The patient was identified as COMT HPS/HPS diplotype carrier and CYP2D6 intermediate metabolizer. CYP2D6 is mainly responsible for the bioactivation of oxycodone into oxymorphone. Reduced CYP2D6 activity may result in a lower oxycodone activ
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet-
Bollinger et al. find that genetic predispositions in CYP2D6 and catechol-O-methyltransferase contribute to high pain sensitivity and analgesic therapy failure in a fibromyalgia patient, suggesting the need for further study. Learn more in #PainReports https://t.co/9qSqW6ily9 https://t.co/IBLonXxQZP
-
-
Mashup Score: 4April 2025 - Volume 10 - Issue 2 : PAIN Reports - 10 day(s) ago
The open home of global research and emerging pain science, PAIN Reports is an official publication of IASP. View free articles at and learn more today!
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
between degeneration and pain. We hypothesize that DNA methylation, an epigenetic mechanism previously linked to discogenic LBP, is dysregulated in symptomatic vs asymptomatic IVDs. Objectives: Identify differentially methylated genes and pathways in symptomatic vs asymptomatic IVDs. Methods: Three lumbar IVDs with similar degeneration severity were tested prior to surgery by discography to identify symptomatic IVDs. Methylation analysis was performed on ∼935,000 cytosine guanine dinucleotide sites on nucleus pulposus DNA. We explored differential methylation and pathway enrichment on cytosine guanine dinucleotide sites located within the promoter regions of genes. Results: Two IVDs (L3/L4 and L4/L5) evoked pain ratings of 10/10 and 8/10, one IVD (L5/S1) scored 0/10. DNA methylation differed between symptomatic and asymptomatic IVDs. Several identified genes have roles in extracellular matrix remodeling. Other differentially methylated genes were related to immunomodulation and ion cha
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4April 2025 - Volume 10 - Issue 2 : PAIN Reports - 13 day(s) ago
The open home of global research and emerging pain science, PAIN Reports is an official publication of IASP. View free articles at and learn more today!
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
t. Methods: This randomized clinical trial was a simple blind, monocentric, placebo-controlled study. Seventy-five patients were randomly distributed between standard and sham OMT sessions at a 1:1 ratio, receiving standard or sham treatment every 2 days for the 7 days of the study. Patients were assessed using a self-administered visual analog scale (VAS)—ranging from 0 to 100, recorded in the morning and evening. They also completed the QLQ-C15-PAL quality-of-life questionnaire on the first and last day of the study. For participants with controlled analgesia pumps, the number of analgesic doses was recorded. Results: The OMT group demonstrated a significant effect of days, circadian period, and group on VAS pain decrease (P < 0.05). The VAS pain score for the OMT group exhibited a notable decline from the third day (D3 pm) (P = 0.03) to D6 pm (P = 1.28 × 10−05) with 43.2% improvement by the conclusion of the study. On D6, the quality-of-life score exhibited a tendency towards improv
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
ted patient-reported outcomes (PROs) have not been extensively studied. Objective: Based on registry data, this study compared pain intensities summarized as a pain composite score (PCS) and postoperative opioid use between PNBc and PNBs nerve blocks in patients undergoing TKA, and evaluated additional PROs. Methods: Data from 4,328 adults undergoing TKA enrolled in the PAIN OUT registry (ClinicalTrials.gov NCT02083835) were analyzed. Patients were categorized into general anesthesia (GA) or spinal anesthesia (SA), with subgroups general anesthesia only (GA-o) or spinal anesthesia only (SA-o), and combinations with single-injection PNB (GA&PNBs and SA&PNBs) or continuous PNB via catheter (GA&PNBc and SA&PNBc). The primary end point was PCS, summarizing pain intensities and time in severe pain during the first 24 hours. Secondary end points included opioid use and additional PROs. Results: The use of GA&PNBc was associated with a higher PCS (+0.5 [0.0-0.9], P = 0.035) compared with GA&P
Source: journals.lww.comCategories: General Medicine News, RheumatologyTweet
To determine the optimal definition for detecting chronic pain with dysfunction, Shibata et al. find that the criteria of duration and frequency are acceptable while the intensity risked overlooking them. Learn more in #PainReports https://t.co/Lod7jqz3yL https://t.co/EYn9BJmivY